Hemogenyx Pharmaceuticals PLC is a pre-clinical stage biopharmaceutical company dedicated to developing new medicines and treatments for blood and autoimmune diseases. With its headquarters in London and research facilities in New York City, the company is committed to bringing breakthrough cell therapy and immunotherapies to patients in need. For over 50 years, bone marrow transplantation has been a life-saving treatment for patients with blood diseases, but its limited use due to associated risks of toxicity and death has been a challenge.

Hemogenyx Pharmaceuticals has developed innovative technology that has the potential to revolutionize the field by enabling a greater number of patients to benefit from bone marrow transplantation. The company is focused on addressing devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases like multiple sclerosis and lupus. By delivering groundbreaking therapies, Hemogenyx Pharmaceuticals aims to transform lives and bring hope to patients with serious or life-threatening conditions.

With a strong mission and core values of integrity, courage, and ingenuity, the company is dedicated to realizing unique treatment opportunities for patients and value for investors